Bilosomes as a promising nanoplatform for oral delivery of an alkaloid nutraceutical: improved pharmacokinetic profile and snowballed hypoglycemic effect in diabetic rats. (31st December 2022)

• Record Type: Journal Article
• Authors: Elkomy, Mohammed H.; Eid, Hussein M.; Elmowafy, Mohammed; Shalaby, Khaled; Zafar, Ameeduzzafar; Abdelgawad, Mohamed A.; Rateb, Mostafa E.; Ali, Mohammed R.A.; Alsalahat, Izzeddin; Abou-Taleb, Heba A.
• Is Part Of: Drug delivery. Volume 29:Number 1(2022)
• Page Start: 2694
• Page End: 2704
• Publication Date: 2022-12-31
• Subjects: Berberine -- diabetes mellitus -- bilosomes -- bioavailability -- pharmacokinetics -- bile salts -- optimization; Drug delivery systems -- Periodicals; Drug targeting -- Periodicals; 615.05
• DOI: 10.1080/10717544.2022.2110997
• Languages: English
• ISSNs: 1071-7544

Abstract

Abstract: Diabetes mellitus is a life-threatening metabolic disease. At the moment, there is no effective treatment available to combat it. In this study, we aimed to develop berberine-loaded bilosomes (BER-BLS) to boost the oral bioavailability and therapeutic efficacy of berberine, a natural antidiabetic medication. The BER-BLS was fabricated using a thin-film hydration strategy and optimized using a central composite design (face-centered). The average vesicle size, entrapment efficiency, and surface charge of the optimized BER-BLS preparation were 196.5 nm, 89.7%, (−) 36.4 mV, respectively. In addition, it exhibited higher stability and better-sustained release of berberine than the berberine solution (BER-SOL). BER-BLS and BER-SOL were administered to streptozocin-induced diabetic rats. The optimized BER-BLS formulation had a significant hypoglycemic impact, with a maximum blood glucose decrease of 41%, whereas BER-SOL only reduced blood glucose by 19%. Furthermore, the pharmacological effect of oral BER-BLS and BER-SOL corresponded to 99.3% and 31.7%, respectively, when compared to subcutaneous insulin (1 IU). A pharmacokinetic analysis found a 6.4-fold rise in the relative bioavailability of berberine in BER-BLS when compared to BER-SOL at a dosage of 100 mg/kg body weight. Histopathological investigation revealed that BER-BLS is suitable for oral administration. Our data demonstrate that BLS is a potential nanocarrier for berberine administration, enhancing its oral bioavailability and antidiabetic activity.